Panviral is politically contentious – CEPI solves and avoids the problem
Jennifer Kahn 4-21-2020 UC Berkeley Graduate School of Journalism “How Scientists Could Stop the Next Pandemic Before It Starts” New York Times Magazine https://www.nytimes.com/2020/04/21/magazine/pandemic-vaccine.html (ermo/sms, Acc:6-22-2022)
Governments, meanwhile, have been reluctant to fund panviral development — both because it’s expensive and because the rewards can feel remote, especially as many diseases originate in other countries. “We don’t prevent well; we respond well,” Daszak notes. “Remember when Obama got $5 billion for the Ebola outbreak in West Africa, and U.S. troops went to help fix the problem? That’s heroic. How heroic is it, three years before Ebola, to say, ‘We’re going to fund a massive program in West Africa to help these poor countries get ready in case an outbreak happens?’ He’d be laughed out of the room!”
Global nonprofits like the Gates Foundation have tried to step into this funding void. The foundation has supported GAVI, an international alliance that helps vaccinate children in poor countries and spearheaded a fund to fight H.I.V., tuberculosis and malaria worldwide. Mark Suzman, the chief executive of the Gates Foundation, says that when governments and companies do pull together, the focus is often on projects like these rather than “forward-looking” issues like pandemics or climate change. One exception, he says, has been CEPI, the Coalition for Epidemic Preparedness Innovations, an NGO that was founded in 2017 to coordinate and finance the development of new vaccines for diseases that might lead to a pandemic. When it started, Suzman told me, CEPI was a low-profile project: “It was really a response to the Ebola epidemic of 2014 and 2015. Now, of course, it looks incredibly farsighted.”
CEPI works by identifying the most promising research, and then connecting it to industry and government resources, in order to bring multiple sets of “candidate” vaccines through initial clinical trials. The goal is to create a stockpile of potential treatments for known coronaviruses, hemorrhagic fevers and other global threats that could quickly go into production in the event of an epidemic. Daszak noted that CEPI is running a trial for a vaccine against Nipah virus, a zoonotic virus — one that exists in animals but can infect people — which can cause acute respiratory illness and fatal encephalitis. “This is the classic example,” Daszak says. “So far, there have been only a few outbreaks, so the market is minuscule: a few thousand people a year get it, in Malaysia or Bangladesh. But it infects a wide range of animals, and that means it’s likely to keep crossing over into people. And if it ever broke out, it could be a pandemic with very lethal consequences.”
The group also funds technologies aimed at “Disease X” (the potentially pandemic viruses that we have yet to discover) with the goal of faster vaccine development should a totally new threat emerge. As Jake Glanville, whose company, Distributed Bio, received a grant from Gates Foundation to create a universal flu vaccine, told me, “This is how we win the forever war, and not just battles against these pathogens.”
CEPI isn’t the only group trying to find solutions to the drug and vaccine problems. In the United States, a federally funded university collective called the Antiviral Drug Discovery and Development Center (AD3C) was created in 2014, with the goal of developing drugs for influenza, flaviviruses (including West Nile), coronaviruses and alphaviruses. Like CEPI, AD3C partners with pharmaceutical companies but focuses on salvaging and reformulating promising drugs that might be valuable but that the company isn’t interested in pursuing. (When Gilead discovered that remdesivir worked on coronaviruses, for instance, the treatment was routed to AD3C, which enlisted scientists at Vanderbilt University and the University of North Carolina to repurpose it.)